Dermatological Drugs - Central Asia

Central Asia

The Dermatological Drugs market in Central Asia is anticipated to witness a significant growth in revenue, reaching a projected value of US$22.69m in 2024.
This growth is expected to continue with an annual growth rate (CAGR 2024-2029) of 6.87%, leading to a market volume of US$31.63m by 2029.
When compared globally, United States is expected to generate the highest revenue in the Dermatological Drugs market, estimated to be US$11,670.00m in 2024.
Central Asia's dermatological drugs market is experiencing rapid growth due to increasing demand for skincare products in the region.

Key regions: United Kingdom, Canada, Japan, Europe, China

Market

Region

Region comparison

Currency

Analyst Opinion

The demand for dermatological drugs in Central Asia has been steadily increasing in recent years.

Customer preferences: Customers in Central Asia are becoming more aware of the importance of skincare and are willing to invest in high-quality dermatological drugs. They prefer products that are effective, affordable, and easily accessible.

Trends in the market: Kazakhstan is the largest market for dermatological drugs in Central Asia, followed by Uzbekistan and Kyrgyzstan. The market is dominated by topical drugs, such as creams and ointments, which are widely used to treat common skin conditions such as acne, eczema, and psoriasis. The demand for oral drugs is also increasing, particularly for severe skin conditions such as dermatitis and skin cancer.

Local special circumstances: Central Asia is known for its harsh climate, which can cause a range of skin problems. The dry and arid climate in the region can lead to dry skin, while the high altitude can increase the risk of sunburn and skin cancer. Additionally, traditional medicine is still widely used in the region, and many consumers prefer natural remedies to synthetic drugs.

Underlying macroeconomic factors: The growing middle class in Central Asia has increased demand for dermatological drugs. Rising incomes and improved access to healthcare have also contributed to the growth of the market. However, the market is still relatively underdeveloped compared to other regions, and there is significant potential for growth in the coming years.

Methodology

Data coverage:

Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.

Modeling approach / Market size:

Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.

Forecasts:

In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.

Additional notes:

Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.